Medtronic: Endeavour Resolute DES maintains strong efficacy

Medtronic has announced that of the patients treated with its Endeavour Resolute drug-eluting stent (DES) in the Resolute IDE trial, only two needed repeat procedures at two years following implant.

The firm states this is a “remarkably low” 1.5 per cent rate of target lesion revascularisation.

In addition, the firm states there were no instances of stent thrombosis among the 130 research participants, through the 24 months of follow-up.

Sean Salmon, vice-president and general manager of the coronary and peripheral vascular business at Medtronic, states the goal of the Resolute clinical programme it to extend the long-term safety and efficacy benefits that the DES offers to individuals underserved by currently available treatment alternatives.

“The Resolute DES will complement our coronary stent portfolio as we seek to address the unmet clinical needs of patients at high risk of restenosis,” he adds.

According to the company, the Endeavour Resolute zotarolimus-eluting coronary stent system is available in over 100 countries outside the USA, where it is limited to investigational use under an exemption granted by the country’s Food and Drug Administration.

In recent days, Medtronic announced its plans for the Transcatheter Cardiovascualr Therapeutics meeting, which takes place in Washington DC from October 12th – 17th.